GLUCOTRACK ANNOUNCES EXPANSION OF ITS CONTINUOUS GLUCOSE MONITORING TECHNOLOGY TO EPIDURAL GLUCOSE MONITORING
April 16, 2024 08:30 ET
|
GlucoTrack, Inc.
Expansion offers the potential for continuous, discreet and simplified epidural glucose monitoring solutions for patients with Painful Diabetic Neuropathy Rutherford, NJ, April 16, 2024 (GLOBE...
GLUCOTRACK ANNOUNCES INCREASED SENSOR LONGEVITY FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR
April 02, 2024 08:30 ET
|
GlucoTrack, Inc.
Computational modeling with The Technology Partnership shows sensor longevity beyond 3 years; 1 year longer than previously announced Implantable Continuous Blood Glucose Monitor technology could...
GLUCOTRACK EXPANDS LEADERSHIP TEAM WITH NEW VICE PRESIDENT OF QUALITY
March 12, 2024 09:30 ET
|
GlucoTrack, Inc.
Rutherford, NJ, March 12, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization...
GLUCOTRACK SELECTS CIRTEC MEDICAL AS MANUFACTURER FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR
February 27, 2024 08:30 ET
|
GlucoTrack, Inc.
Rutherford, NJ & Brooklyn Park, MN, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel...
GLUCOTRACK ANNOUNCES THE APPOINTMENT OF LUIS MALAVÉ TO CHAIR OF THE BOARD OF DIRECTORS
February 13, 2024 09:30 ET
|
GlucoTrack, Inc.
Rutherford, NJ, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization...
GLUCOTRACK ANNOUNCES EARLY ACCURACY DATA FOR ITS IMPLANTABLE CONTINUOUS GLUCOSE MONITOR
January 02, 2024 12:33 ET
|
GlucoTrack, Inc.
Rutherford, NJ, Jan. 02, 2024 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device company focused on the design, development, and commercialization...
GLUCOTRACK ANNOUNCES 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
November 30, 2023 17:39 ET
|
GlucoTrack, Inc.
Rutherford, NJ, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with...
GLUCOTRACK ANNOUNCES SHAREHOLDER UPDATE
November 13, 2023 09:00 ET
|
GlucoTrack, Inc.
Rutherford, NJ, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with...
GLUCOTRACK ANNOUNCES PRECLINICAL TESTING WITH IMPLANTABLE CONTINUOUS GLUCOSE MONITOR
October 12, 2023 08:30 ET
|
GlucoTrack, Inc.
Rutherford, NJ, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with...
GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ERIN CARTER TO BOARD OF DIRECTORS
August 31, 2023 08:30 ET
|
GlucoTrack, Inc.
Rutherford, NJ, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with...